Hepatitis B virus neutralization with DNA origami nanoshells
Abstract
We demonstrate the use of DNA origami to create virus-trapping nanoshells that efficiently neutralize hepatitis B virus (HBV) in cell culture. By modifying the shells with a synthetic monoclonal antibody that binds to the HBV envelope, the effective neutralization potency per antibody is increased by approximately 100 times compared to using free antibodies. The improvements in neutralizing the virus are attributed to two factors: first, the shells act as a physical barrier that block the virus from interacting with host cells; second, the multivalent binding of the antibodies inside the shells lead to stronger attachment to the trapped virus, a phenomenon known as avidity. Pre-incubation of shells with HBV and simultaneous addition of both components separately to cells lead to comparable levels of neutralization, indicating rapid trapping of the virions by the shells. Our study highlights the potential of the DNA shell system to rationally create novel antivirals using components that, when used individually, show little to no antiviral effectiveness.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PreS1-decorated recombinant adenovirus encoding HBV antigens generates neutralizing humoral and cellular immunity
Rebecca A Russell, James B. Lok, … Matthew D. J. Dicks·bioRxiv·Jan 30, 2026
- Engineering Versatile Two-Dimensional Nanobody-Origami Architectures for Enhanced Antiviral Activity
Tingjie Song, Jazmin Galván Achi, … Xing Wang·bioRxiv·Jun 27, 2025
- Therapeutic Potential of the Novel Monoclonal Antibody 7-4G against HBsAg in a Mouse Model of Chronic Hepatitis B Virus Infection
Maidina Abuduwaili, Grace Naswa Makokha, … Kazuaki Chayama·bioRxiv·Jul 26, 2026
- Hybrid peptide DNA nanomaterials enable potent and broad-spectrum virus neutralization
Saurabh Umrao, Abhisek Dwivedy, … Xing Wang·bioRxiv·Jul 21, 2025
- Preclinical antiviral study of a liver-targeted TLR1/2 agonist in an immune-competent mouse model of HBV infection
Fanny Charriaud, Myriam Lamrayah, … David Durantel·bioRxiv·May 27, 2026
- NEDD4-binding protein 1 suppresses HBV replication by degrading HBV RNAs
N. Kobayashi, S. Suzuki, … T. Fukuhara·bioRxiv·Oct 6, 2023